Skip to main content
Log in

Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours

  • Research Article
  • Published:
Tumor Biology

Abstract

The classification of ameloblastoma in multicystic or unicystic variants is associated with its clinical behaviour. Recently, BRAF and SMO mutations have been reported in ameloblastomas. However, it is not clear if such mutations are shared by the multi- and unicystic variants of ameloblastoma or by odontogenic carcinomas. We assessed BRAFV600E and SMOF412E in multicystic, unicystic and desmoplastic ameloblastomas. In addition, we investigated whether the BRAFV600E mutation occurs in odontogenic carcinomas. A total of 28 formalin-fixed paraffin-embedded samples, comprising 17 ameloblastomas and 11 odontogenic carcinomas, were included. The BRAFV600E mutation was assessed by real-time PCR with a specific TaqMan probe and confirmed by Sanger sequencing. The SMOF412E mutation was assessed by Sanger sequencing. Fourteen out of 17 (82 %) ameloblastomas showed the BRAFV600E mutation, specifically, 5/6 (83 %) unicystic, 7/9 (78 %) multicystic and 2/2 desmoplastic ameloblastomas. BRAFV600E mutation was detected in 4/11 (36 %) malignant tumours, specifically, 3/8 (38 %) ameloblastic carcinomas and 1/1 clear cell odontogenic carcinoma, while the two ghost cell odontogenic carcinomas did not harbour this mutation. The SMOF412E mutation was not detected in ameloblastoma. The BRAFV600E-activating mutation is a common event in ameloblastomas, occurring regardless of site or histological type. This mutation is also detected in odontogenic carcinomas. SMO somatic mutation is a secondary genetic event in the ameloblastoma pathogenesis. Our findings support the possibility for personalised, molecular-targeted therapy for ameloblastomas and odontogenic carcinomas harbouring the BRAFV600E mutation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Barnes L, Eveson JW, Reichart P, Sidransky D. (eds.) (2005) World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. IARC Press, Lyon

  2. Hertog D, van der Waal I. Ameloblastoma of the jaws. A critical reappraisal based on a 40-years single institution experience. Oral Oncol. 2010;46(1):61–4.

    Article  PubMed  Google Scholar 

  3. Hall JM, Weathers DR, Unni KK. Ameloblastic carcinoma: an analysis of 14 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103(6):799–807.

    Article  PubMed  Google Scholar 

  4. Neville B, Damm DD, Allen CM, Bouquot J. Oral and maxillofacial pathology. Philadelphia: WB Saunders; 2009.

    Google Scholar 

  5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.

    Article  CAS  PubMed  Google Scholar 

  6. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta. 2003;1653(1):25–40.

    CAS  PubMed  Google Scholar 

  7. Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS. Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res. 2014;20(21):5517–26.

    Article  CAS  PubMed  Google Scholar 

  8. Kurppa KJ, Catón J, Morgan PR, Ristimäki A, Ruhin B, Kellokoski J, et al. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol. 2014;232(5):492–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahring L, Kwei KA, et al. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet. 2014;46(7):722–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Gomes CC, Diniz MG, Gomez RS. Progress towards personalized medicine for ameloblastoma. J Pathol. 2014;232(5):488–91.

    Article  CAS  PubMed  Google Scholar 

  11. Ackerman GL, Altini M, Shear M. The unicystic ameloblastoma: a clinicopathologic study of 57 cases. J Oral Pathol. 1988;17(9–10):541–6.

    Article  Google Scholar 

  12. Marino-Enriquez A, Fletcher CDM. Shouldn’t we care about the biology of benign tumours. Nat Rev Cancer. 2014;14:701–2.

    Article  CAS  PubMed  Google Scholar 

  13. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol. 2005;15(3):249–54.

    Article  CAS  PubMed  Google Scholar 

  14. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky Jr WE, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009;41(5):544–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the National Council for Scientific and Technological Development (CNPq)/Brazil, Coordination for the Improvement of Higher Education Personnel (CAPES)/Brazil and “Fundação de Amparo a Pesquisa do Estado de Minas Gerais” (FAPEMIG)/Brazil. RS Gomez and CC Gomes are research fellows at CNPq/Brazil.

Conflicts of interest

None

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ricardo Santiago Gomez.

Additional information

The correspondent author is the Guarantor of Submission.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Diniz, M.G., Gomes, C.C., Guimarães, B.V.A. et al. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours. Tumor Biol. 36, 5649–5653 (2015). https://doi.org/10.1007/s13277-015-3238-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3238-0

Keywords

Navigation